Abstract
Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV encoded transgenes, raising the potential for their use in vaccine development. In this review, we have summarized current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
Current Gene Therapy
Title: Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Volume: 2 Issue: 4
Author(s): J. Y. Sun, S. Chatterjee and K. K. Wong, Jr.
Affiliation:
Abstract: Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV encoded transgenes, raising the potential for their use in vaccine development. In this review, we have summarized current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
Export Options
About this article
Cite this article as:
Sun Y. J., Chatterjee S. and Wong, Jr. K. K., Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347616
DOI https://dx.doi.org/10.2174/1566523023347616 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, further converted to melatonin by ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Using Bioinformatics Techniques for Gene Identification in Drug Discovery and Development
Current Drug Metabolism Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
Current Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Histogram Feature Analysis of Tumor Body on Diffusion-weighted MR Imaging in Differentiation between Granulosa Cell Tumors and Other Sex-cord Tumors in Ovary: Comparison with Histological Results
Current Medical Imaging Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)
Current Medicinal Chemistry Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types
Mini-Reviews in Medicinal Chemistry Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Current Pharmaceutical Design A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Medicinal, Pharmacological and Biochemical Progress on the Study of Genus <i>Helianthemum</i>: A Review
Current Chemical Biology Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors
Anti-Cancer Agents in Medicinal Chemistry A Review of Himalayan Medicinal Plants against Cancer
Current Traditional Medicine Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Coexistence of Hodgkin and Non-Hodgkin Lymphoma; Composite Lymphoma [CL] in a Patient Presenting with Waxing and Waning Lymphadenopathy
Cardiovascular & Hematological Disorders-Drug Targets